BMS’ Opdivo+Yervoy could become first choice for certain colorectal cancer patientsBristol-Myers Squibb’s Opdivo and Yervoy combination could become first line treatment for a small group of metastatic colorectal Share XBMS’ Opdivo+Yervoy could become first choice for certain colorectal cancer patientshttps://pharmaphorum.com/news/bms-opdivoyervoy-could-become-first-choice-for-certain-colorectal-cancer-patients/
BMS immunotherapy combo approved in new colorectal useBristol-Myers Squibb’s Opdivo and Yervoy has become the first approved immunotherapy combination option for a group of patients Share XBMS immunotherapy combo approved in new colorectal usehttps://pharmaphorum.com/news/bms-immunotherapy-combo-approved-in-new-colorectal-use/
